Zymeworks Inc. (NASDAQ: ZYME), a Canada-based clinical-stage biotechnology company, on Monday reported a wider net loss for the fourth quarter of fiscal 2025, reflecting a sharp decline in revenues.
- Fourth-quarter revenues declined to $2.51 million from $31.0 million in the corresponding quarter last year
- The company reported a net loss of $41.2 million for Q4, compared to a loss $23.5 million a year earlier
- On a per-share basis, the fourth-quarter loss widened to $0.55 from $0.31 in the year-ago quarter
- As of December 31, 2025, the company had $270.6 million in cash, cash equivalents, and marketable securities
- Other income was $2.7 million in Q4, compared to $4.4 million in the prior-year period
- Q4 G&A expenses decreased to $15.4 million from $16.2 million in the fourth quarter of last year
- R&D expenses were $31.2 million in 4Q 2025, versus $37.1 million in the comparable period of 2024
- This month, Zymeworks entered into a $250.0 million royalty-backed note financing arrangement with Royalty Pharma